Search   Advanced Search
LATEST NEWS
 
 
News
 Latest Headlines
 Quick Facts
 Breaking News
 Top Stories
 Feature Articles
 Politics
 US Policy
 General
 Commodities
 Canadian
 UK
 Indian
 Wallstreet Events
 US Economic News
 European Economic News
 Asian Economic News
 All Economic News
 FX Top Stories
 Currency Alerts
 Mkt Sensitive News
 Politics
 European Mkt Updates
 Asian Mkt Updates
 Treasury Mkt Updates
 Pop
 Rock
 Classic Rock
 Rap/Hip-Hop
 Country
 Alternative
 Oldies
 Movie Reviews
 DVD Releases
 Box Office
 Slide Shows
 Business News
Commentary/Analysis
 Daily Market Analysis
 US Market Updates
 US Commentary
 Asian Commentary
 European Commentary
 Canadian Commentary
 Indian Commentary
 Sector/Market Trends
Stock Alerts
 Stocks To Watch
 Long Term Stocks
 Before the Bell
 $5 and Under
 After the Bell
 Intraday Updates
 IPOs
 Hot Stocks
Earnings Calendars
 Upcoming Earnings
 Latest Earnings
 Pos Pre Announcements
 Neg Pre Announcements
Corporate Calendars
 Stock Splits
 Stock Buybacks
 Dividends
 Conference Calls
 FDA Calendar
 Board Meetings
 Mergers & Acquisitions
Ratings Changes
 Upgrades
 Downgrades
 Coverage Initiations
 Coverage Reiterated
 All Videos
 Market Commentary
 Top Stories
 Economic News
 Political News
 Foreign Markets
 Corporate News
 Entertainment News
 Top Stories
 Earnings
 Mergers & Acquisitions
 Market Commentary
 Economic News
 IPOs and New Issues
 Corporate News
 Forex News
 Interviews
 Private Equity
Economic Calendar
RTT DeskAlert

Font Down Font Up
PPD To Spin Off Compound Partnering Business - Update
10/27/2009 9:15 PM ET


RELATED NEWS
PPD Inc. Signs Agreement To Acquire BioDuro - Quick Facts
PPD, Janssen Pharmaceutica Tie-up To Develop Drugs - Update
PPD, Janssen Pharmaceutica Reach Deal To Develop Compounds For Treatment Of Irritable Bowel Syndrome And Bacterial Infections - Quick Facts
PPD Closes Acquisition Of Excel PharmaStudies In China - Quick Facts
Pharmaceutical Product Development Q3 09 Earnings Conference Call At 9:00 AM
(RTTNews) - Tuesday, PPD Inc. (PPDI: News ) announced that its board has authorized management to proceed with preparations to spin off its compound partnering business from its core contract research organization business. PPD expects the transaction to be completed in the middle of 2010. Approval by PPD's shareholders is not required for completion of the spin-off.

The contract research organization, or CRO, business will continue to operate under the PPD name and will be focused solely on its drug discovery and development service businesses and will no longer be coupled with the earnings dilution from the company's compound partnering business.

Fred Eshelman, executive chairman said,"Each company will have the opportunity to focus exclusively on its core strengths, seek new strategic opportunities and compete more effectively in its respective market."

The compound partnering company resulting from the spin-off is expected to have the rights to royalties and sales-based milestones from the company's collaboration with ALZA Corp., a Janssen-Cilag affiliate, on Priligy, the first and only approved treatment for premature ejaculation, which has been approved for marketing in Sweden, Finland, Portugal, Spain, Austria, Germany, Italy, Mexico and South Korea.

PPD said that the company will also have rights to potential future regulatory and sales-based milestones and the statin compound licensed from Ranbaxy Laboratories Ltd. for the treatment of dyslipidemia.
PPD also announced it has entered into an agreement to acquire Excel PharmaStudies, Inc. After the acquisition closes, Excel's more than 300 employees will join PPD, and Mark Engel, co-founder, will work exclusively with PPD as a strategic consultant. The acquisition is subject to various closing conditions and is expected to close in the fourth quarter of 2009.

In addition, the company announced it has signed an agreement to invest $100 million in Celtic Therapeutics Holdings L.P., an investment partnership organized for the purpose of identifying, acquiring and investing in a diversified portfolio of 10 to 15 novel therapeutic product candidates.

Further, PPD announced it has been awarded a contract by the U.S. Food and Drug Administration to evaluate the agency's Center for Drug Evaluation and Research post-market spontaneous adverse event surveillance system.

The award of $2.7 million for year one, is part of a two-year project of FDA's Initiative for Maximizing the Benefit of Passive Adverse Event Collection throughout a Product's Life Cycle. Under the contract, PPD will comprehensively evaluate this FDA public health surveillance system.

To receive FREE breaking news email alerts for Pharmaceutical Product Development and others in your portfolio


 1   2   Next Page 


Share Article:   Del.icio.us    Digg    Y! My Web    Facebook    My Space

Email        Print        

     
Top Stories
Wall Street Closes Lower For The Day, Mixed For The Week

Senate Democrats Fault GOP For Failing To Advance Alternative Health Reforms

New Guidelines Recommend Women Wait Until 21 For Cervical Cancer Screening

"New Moon" Takes Center Stage, Should Post Big Opening Weekend

Valero Energy To Permanently Shutter Delaware City Refinery - Update

Earnings
Escalon Medical Q1 Loss Widens - Quick Facts

Cordy Oilfield Services Q3 Net Loss Narrows - Quick Facts

Triton Energy Slips To Q3 Loss - Quick Facts

Electronic Game Card Revises Q3 Results - Quick Facts

Schneider Power Swings To Profit In Q3 - Quick Facts

US Market Commentary
Bay Street Stocks Slip Slightly Again - Canadian Commentary

Stocks Close Mostly Lower Amid Disappointing Quarterly Results - U.S. Commentary

Stocks Remain Stuck In The Red In Mid-Afternoon Trading - U.S Commentary

Stocks Posting Moderate Losses In Early Afternoon Trading - U.S. Commentary

Stocks Seeing Further Downside In Late Morning Trading - U.S. Commentary

US Economic News
Fed's Fisher: "Too-Big-To-Fail" Must Be Addressed

Philly Fed Index Shows Much Bigger Than Expected Increase In November

Leading Indicators Index Increases For Seventh Straight Month In October

Philly Fed Index Jumps To 16.7 In November

Leading Indicators Index Rose 0.3% In October

Political News
Christian Leaders Unveil "Call To Faith" On Life, Marriage, Religious Freedom

Senate Ethics Committee Admonishes Burris But Finds No Legal Wrongdoing

Senate Democrats Fault GOP For Failing To Advance Alternative Health Reforms

Sen. Nelson Says He Will Vote To Proceed With Debate On Health Care Bill

Sen. Gregg Calls Ron Paul's Fed Audit Amendment "Political Pandering"




 
Markets End Week In Red
11/20/09 04:51
Partisan Debate Precedes Health Reform Vote
11/20/09 03:23
Wall Street Extends Losses
11/20/09 02:13
 

Today's Stocks to Watch
SVN - 7 Days Group Holdings Ltd.
SLW - Silver Wheaton Corp.
CPQQ.OB - China Power Equipment
LIMS - STARLIMS TECHNOLOGY
SPRD - Spreadtrum Communications Inc.
HEAT - SmartHeat Inc


Profit Taking Likely To Contribute To Continued Weakness – RTTNews Daily Market Analysis
The major index futures are currently indicating a notably lower open for stocks on Friday, with the markets likely to see some further downside after closing lower in each of the two previous sessions. With no major economic data on tap for the day, traders have looked to corporate news, including disappointing quarterly results from Dell (DELL). Traders may also continue to cash in on the recent strength in the markets that lifted the major averages to their best closing levels in over a year earlier in the week.

SLIDE SHOW: Pittsburgh Plays Host To Third G-20 Summit World leaders met at the G-20 summit in Pittsburgh, where they promised to maintain economic stimulus agreed to in London in April.
  Trading Center

 

Copyright © 2009 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.

Feedback| Terms of Service | How To Use RTTNews.com| Advertise| Buy Content | RSS